About Us
Board of Directors




Mr. Burgdorf is Chief Operating Officer of Remeditex Ventures. He joins Remeditex after a serving as the Chief Operating Officer and General Counsel of VuCOMP, Inc. while also maintaining a corporate legal practice as a shareholder at the law firm of Beatty, Bangle and Strama. Prior to that, he was the Vice Chancellor and General Counsel of The University of Texas System (2005-2013), a partner at the law firm of Vinson & Elkins (1998-2005), General Counsel of Samsung Austin Semiconductor (1996-1998) and an associate at Vinson & Elkins (1990-1996). Mr. Burgdorf graduated from The University of Texas with a BBA in Finance and International Business, Southern Methodist University with an MBA and The University of Texas with a J.D. He is currently vice chairman of the Board of Regents for Concordia University – Texas, a member of the Board of Directors for The American Heart Association – Austin Chapter, and a member of the American Law Institute. He is a recipient of the Magna Stella Award of The General Counsel Forum for outstanding leadership and management (2011) and Nightingale’s Healthcare Outstanding General Counsel (2006).
Alan Crane is a general partner at Polaris Partners, focusing on building and investing in healthcare companies since 2002. He has served as founder and/or has played a significant role as chairman and chief executive officer (CEO) in the building of six Polaris companies. From 2006 to present, Mr. Crane co-founded and served as CEO of Cerulean Pharma (a public clinical-stage nanopharmaceutical company), co-founded Navitor Pharmaceuticals, co-founded Visterra (a company with novel technology targeting infectious disease) and co-founded XTuit Pharmaceuticals (a company developing tumor microenvironment drugs). From 2002 to 2006, he was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built the company into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis, and raising $275 million. The first product from Momenta's pipeline achieved over $1B during its first year of sales.

Prior to Polaris, Mr. Crane was Senior Vice President of global corporate development at Millennium Pharmaceuticals. He was responsible for leading Millennium's strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development-stage products, including Velcade® that became the main basis of the company's $9B acquisition by Takeda. In addition to serving as Chairman of Navitor, he serves on the boards of Cerulean Pharma (Chairman), T2 Biosystems, Ocular Therapeutix, Seventh Sense Biosystems, XTuit Pharmaceuticals (Chairman), and Vaccinex. Previously, he served on the boards of Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline) and Adnexus (acquired by Bristol-Myers Squibb).

Mr. Crane received his MBA in 1992, and his BA summa cum laude and MA in 1986, all from Harvard University. He also attended Harvard Medical School, from 1986 to 1988, before pursuing a business career.
Jean-François Formela is a partner in the life sciences group at Atlas Venture and focuses on new advances in biology and drug discovery technologies. Specializing in venture creation, he spearheaded the AVDC (Atlas Venture Development Corporation) model, from which Annovation Biopharma, Arteaus Therapeutics (acquired by Eli Lilly and Company, NYSE: LLY) and Ataxion were born. Dr. Formela was also behind Atlas’ collaboration with Monsanto Company. In addition to Navitor, he serves on the boards of Annovation Biopharma, Ataxion, F-star and Spero Therapeutics and is the chairman of Egalet, as well as RaNA Therapeutics, which he co-founded.

Dr. Formela has been involved in the formation of companies such as Adnexus (acquired by BMS), Archemix, ArQule (NASDAQ: ARQL), Cellzome (acquired by GlaxoSmithKline), deCODE (acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM), and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Eli Lilly and Company). He was also an investor in CoStim Pharmaceuticals (acquired by Novartis) and Achillion (NASDAQ: ACHN) and a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).

Dr. Formela joined Atlas Venture in 1993 to build its U.S. life sciences franchise. Prior to joining Atlas, he worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. He began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris. Dr. Formela is a member of the Massachusetts General Hospital Research Advisory Council and a trustee of the Boston Institute of Contemporary Art. He received his MD from Paris University School of Medicine and his MBA from Columbia University.
Dr. Friedman served as Chief Executive Officer of Incyte from 2001 and was President of the company from 2004 until his retirement in January 2014. From 1998 until October 2001, Dr. Friedman served as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), from 1994 to 1998 he served as President of Research and Development of The DuPont Merck Pharmaceutical Company, and from 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. Dr. Friedman is also a director of public companies Incyte Corporation, Cerulean Pharma, Synta Pharmaceuticals and Verastem and private biopharmaceutical companies Navitor Pharmaceuticals and Gliknik. Dr. Friedman was a director of Bausch & Lomb, Sirtris Pharmaceuticals, Durata Therapeutics and Auxilium Pharmaceuticals until the acquisition of each of these companies. Dr. Friedman received his AB from Princeton University and his MD from Harvard Medical School.
Brian M. Gallagher, Jr., PhD is a Partner at SR One Ltd. He established the SR One Boston office in 2010, and is focused on building innovative therapeutic and life science companies. In addition to Navitor, Dr. Gallagher currently represents SR One on the boards of Aileron Therapeutics, CalciMedica, Constellation Pharmaceuticals, Nimbus Discovery, RaNA Therapeutics, and River Vision. He previously led the firm's investments in Dicerna Pharmaceuticals (NASDAQ: DRNA) and SpringLeaf Therapeutics. Dr. Gallagher has more than 15 years of investing, business development, operational and R&D experience in both biotechnology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals, where he was responsible for corporate development and operations, as well as post-merger integration following the $720M acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Dr. Gallagher was with Alantos Pharmaceuticals, where he played key roles in R&D and business development activities and led many aspects of the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007.

Dr. Gallagher began his career in R&D at the Japanese pharma Eisai, where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas. He is an inventor on over 25 patents and patent applications and is the senior author of a number of scientific publications. He currently serves on the industry advisory boards for New York University Medical School and the National Brain Tumor Society and is a mentor for MassBio MassCONNECT and a peer reviewer/editorial board member for numerous journals and research funding authorities.

Dr. Gallagher received his BS in Chemistry from The University of Massachusetts, where he was a Shapiro scholar, and his MS and PhD degrees in Organic Chemistry from The University of Michigan.
David Madden is a pharmaceutical industry veteran. He is founder and principal with Narrow River Management, LP, an investment management company with a focus on equity investment in, and management of, drug development projects. Since 2009, he has served as chairman of the board of directors of Dicerna Pharmaceuticals.

From 2000 to 2003, Mr. Madden was co-CEO of Royalty Pharma AG, a private investment management firm specializing in the acquisition of royalty interests in pharmaceutical products. Prior to that position, he was a managing member of Pharmaceutical Partners, LLC, and was president, CEO and a director of Selectide Corporation, a development-stage pharmaceutical company, which was acquired by Marion Merrill Dow in 1995. Additionally, Mr. Madden served as chairman of the board of Adolor Corporation, and is a member of the board of directors of the Hospital for Special Surgery in New York City.

Mr. Madden holds a B.S. in electrical engineering from Union College and an M.B.A. from Columbia University.
Marian Nakada, PhD, joined Johnson & Johnson Innovation–JJDC, Inc. in 2013. She is based in Boston, Mass.

Previously, Dr. Nakada was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson’s Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R&D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy.

Dr. Nakada joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Dr. Nakada joined the Business Development group, where she participated in executing technology licenses for the Johnson & Johnson Pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor's technologies were competitive with the industry.

Dr. Nakada has authored 62 peer-reviewed publications and 14 book chapters and reviews. She holds a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.
Vinzenz Ploerer is Brace Pharma Capital’s President and CEO, and sits on the Board of Directors. Vinzenz has worked as a life science executive for over 20 years, and brings extensive leadership experience in operations, acquisitions and business development. Prior to launching Brace in 2013, he worked at EMS S/A as Senior Vice President of Strategy and Operations. He has also held multiple senior leadership positions at Novartis/Sandoz including various country head roles. Vinzenz currently sits on several corporate boards including GeNO, Therabron, Tyrogenex and Navitor. Vinzenz obtained his Masters of Business Administration from the University of Innsbruck.